Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 beat, “strong” 2025 guidance and ...

In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands against other best weight loss drug stocks to buy according to analysts. Most people have ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript February 28, 2025 Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.10031 EPS ...

Revenue: US$2.79b (up 17% from FY 2023). Net loss: US$116.9m (loss widened by 39% from FY 2023). US$0.38 loss per share. Revenue was in line with analyst estimates. Earnings per share (EPS) missed ...

Anthony Dimeo; Head-Investor Relations; Amneal Pharmaceuticals Inc. Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc. Chintu Patel; Co-Chief ...

Amneal Pharmaceuticals (NASDAQ:AMRX) Inc. reported its Q4 2024 earnings, revealing a slight miss on earnings per share (EPS) expectations, while revenue exceeded forecasts. The company's EPS came ...

Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...

BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...